Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity.
about
Pseudovirions as vehicles for the delivery of siRNAAn attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challengeA spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.Replication-Competent Controlled Herpes Simplex Virus.Systems vaccinology: Enabling rational vaccine design with systems biological approaches.HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceEquine herpesvirus type 1 modified live virus vaccines: quo vaditis?Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virusHSV-1 amplicon vectors: a promising and versatile tool for gene delivery.Recombinant varicella-zoster virus vaccines as platforms for expression of foreign antigens.HSV-1-derived amplicon vectors: recent technological improvements and remaining difficulties--a review.HSV Recombinant Vectors for Gene Therapy.Viruses - from pathogens to vaccine carriersPre-existing immunity against vaccine vectors--friend or foe?A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus.Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.Development of a novel mechanism-based glycolipid adjuvant for vaccination.
P2860
Q24634231-BAC97D9E-C650-4D34-9B77-539CAAF10727Q33916162-BCF80134-E806-43AA-A976-6DD9883F1CE1Q33964131-8D645000-7A92-4DE5-AEE6-FC6F73E90306Q36086213-63B6FF9B-6B77-4ED2-AC47-49DAA27857F1Q36090112-D44F90C8-D34B-4947-8008-8FFCDA8E4DD9Q36156347-25D9D97A-F187-4B6D-9D63-24984A7E2C25Q36383825-688389F4-097D-43D2-8C4D-886D1AE48501Q36879345-C75896F1-0C86-4074-B8B7-215653CD7B00Q36897379-4E5D6766-B56B-4B93-B821-6A0974502EF2Q36969576-DCDD20A6-EF26-455A-A3E9-741E6D4A6466Q37528088-2E10840F-D18C-4B83-B44E-05626FC8AEF1Q37787777-50CE4FDF-131F-47FB-A90F-93178B75B43DQ37946370-BDE9B9E1-9203-4CD1-B3B2-D11B05AC5D52Q38061876-9D91A602-36D1-4362-9969-624D998139E0Q38353693-FA64202B-FBCF-40CD-A5B6-BC08C267BDE5Q45872770-A50F7623-EF63-4AB0-B3FA-244295CC96A6Q55293243-923D787E-84AF-4898-9C43-0D4674C43593
P2860
Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Reduced immune responses after ...... resence of antiviral immunity.
@en
Reduced immune responses after ...... resence of antiviral immunity.
@nl
type
label
Reduced immune responses after ...... resence of antiviral immunity.
@en
Reduced immune responses after ...... resence of antiviral immunity.
@nl
prefLabel
Reduced immune responses after ...... resence of antiviral immunity.
@en
Reduced immune responses after ...... resence of antiviral immunity.
@nl
P2093
P356
P1476
Reduced immune responses after ...... resence of antiviral immunity.
@en
P2093
Alberto L Epstein
Christine Ried
Henning Lauterbach
Thomas Brocker
P304
P356
10.1099/VIR.0.81104-0
P407
P577
2005-09-01T00:00:00Z